9th Annual Biomarkers Congress
10th International Congress on The Future of Breast Cancer
Hotel del Coronado
1500 Orange Ave.
Coronado, California 92118
http://BreastCongress.CancerLearning.com
   Speakers
   --------

   Joyce O'Shaughnessy

   Overview and Purpose
   The 10th International Congress on the Future of Breast Cancer is an
   educational and scientific meeting that focuses on the clinical
   implications of breast cancer genetic and phenotypic subtyping. New
   data and promising studies that provide information about how to
   optimally individualize breast cancer therapy will be discussed, and
   controversial issues will be debated. In addition, strategies for
   optimizing the use of endocrine therapy, conventional chemotherapy,
   and targeted therapies will be presented, and evolving diagnostic
   approaches to identify the driving mutations or pathways in breast
   cancer will be thoroughly discussed along with the therapies targeting
   those mutations. Controversial issues in the surgical and
   radiotherapeutic management of breast cancer will also be discussed
   and debated. The format will include didactic sessions,
   question-and-answer panel discussions, and ample time for participant
   interaction with faculty.

   Target Audience
   This educational activity is directed toward medical oncologists
   interested in the treatment of patients with breast cancer. Surgical
   and radiation oncologists, fellows, nurse practitioners, nurses,
   physician assistants, pharmacists, researchers, and other health care
   professionals interested in the treatment of breast cancer are also
   invited to attend.

   Learning Objectives
   At the conclusion of this congress, you should be able to:
   • Determine optimal surgical care for patients with breast cancer
   • Incorporate recent advances in radiation therapy into the treatment
   of patients with breast cancer
   • Integrate biomarkers, genomic assays, and other risk assessment
   tools into treatment decision making for breast cancer
   • Employ optimal strategies for endocrine therapy and management of
   bone health for patients with hormone receptor–positive breast cancer
   • Identify appropriate strategies for the use of cytotoxic agents in
   the treatment of patients with early-stage and advanced/refractory
   breast cancer
   • Design treatment strategies for patients with HER2-overexpressing
   breast cancer, including novel agents, combinatorial therapies, and
   options for patients who progress on standard therapy
   • Utilize targeted agents in the treatment of HER2– breast cancer
   • Select eligible patients with breast cancer for promising clinical
   trials

   Topics include:
   • Therapeutic Implications of DNA Repair Defects in Breast Cancer
   • The Bone Microenvironment and Breast Cancer Outcome
   • Novel Therapeutic Approaches to Overcome Resistance to HER2-Targeted
   Agents
   • Breast Cancer Biology and Benefit From Angiogenesis Inhibitors
   • New Insights Into Preoperative Therapies for HER2-Positive Breast
   Cancer
   • Axillary Dissection: Where Are We in 2011?
   • Update on Accelerated and Partial-Breast Irradiation
   • State-of-the-Art Oncoplastics Advances
   • What’s New in Optimizing Endocrine Therapies?
   • The PI3K Pathway: What You Need to Know
   • Triple-Negative Breast Cancer: Can We Identify Subtypes?
   • Emerging Insights Into Benefit From Novel Cytotoxic Agents
   • Therapeutic Insights Into Targeting Breast Cancer Stem Cells
   • Adjuvant Chemotherapy in 2011
   • Prognostic and Predictive Implications of Obesity: Emerging
   Interventions
   • New Considerations in Biomarkers and Multigene Assays


   1500 Orange Ave., Coronado, CA , 92118, United States

   Loading (May not complete on browsers without Javascript support)...

   Try again

Schedule of Presentations:

Thursday, July 7, 2011
Friday, July 8, 2011
Saturday, July 9, 2011
Sunday, July 10, 2011
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.